507 reports of this reaction
0.9% of all CINACALCET HYDROCHLORIDE reports
#20 most reported adverse reaction
UNEVALUABLE EVENT is the #20 most commonly reported adverse reaction for CINACALCET HYDROCHLORIDE, manufactured by Amgen Inc. There are 507 FDA adverse event reports linking CINACALCET HYDROCHLORIDE to UNEVALUABLE EVENT. This represents approximately 0.9% of all 57,261 adverse event reports for this drug.
Patients taking CINACALCET HYDROCHLORIDE who experience unevaluable event should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
UNEVALUABLE EVENT is a less commonly reported adverse event for CINACALCET HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to unevaluable event, the following adverse reactions have been reported for CINACALCET HYDROCHLORIDE:
The following drugs have also been linked to unevaluable event in FDA adverse event reports:
UNEVALUABLE EVENT has been reported as an adverse event in 507 FDA reports for CINACALCET HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
UNEVALUABLE EVENT accounts for approximately 0.9% of all adverse event reports for CINACALCET HYDROCHLORIDE, making it a notable side effect.
If you experience unevaluable event while taking CINACALCET HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.